Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
- 26 October 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (37) , 4690-4698
Abstract
Alzheimer's disease (AD) is a chronic, age-related, and irreversible brain disorder that typically develops slowly and gets worse over time. The potent auspicious drug candidate for the treatment of AD is supposed to perform the simultaneous modulation of several targets linked to AD. The new therapeutic approach involves drug candidates that are designed to act on multiple targets and have various pharmacological properties. This trend has triggered the development of various multimodal drugs including TV-3326 (i.e. ladostigil) and M-30 (i.e. a new multitarget iron chelator). TV-3326 combines the neurorestorative/neuroprotective effects of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule. M-30, the second derivative of rasagiline, was developed by combining the propargyl moiety of rasagiline into the skeleton of VK-28 (i.e. a novel brain permeable neuroprotective iron chelator). It has been revealed that both the compounds possess anti-AD effects and therefore, the clinical development is directed to the treatment of this type of neurodegenerative diseases (NDs). In this article, we have reviewed the neuroprotective molecular mechanisms and multimodal effects of TV-3326 and M-30.Keywords
This publication has 90 references indexed in Scilit:
- Multi Target Neuroprotective and Neurorestorative Anti-Parkinson and Anti-Alzheimer Drugs Ladostigil and M30 Derived from RasagilineExperimental Neurobiology, 2013
- Sleep-Disordered Breathing, Hypoxia, and Risk of Mild Cognitive Impairment and Dementia in Older WomenJAMA, 2011
- The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell ApoptosisFrontiers in Neuroscience, 2010
- Chronic brain cytochrome oxidase inhibition selectively alters hippocampal cholinergic innervation and impairs memory: Prevention by ladostigilExperimental Neurology, 2007
- The Application of Proteomics and Genomics to the Study of Age-Related Neurodegeneration and NeuroprotectionAntioxidants & Redox Signaling, 2007
- Therapeutic targets and potential of the novel brain‐ permeable multifunctional iron chelator–monoamine oxidase inhibitor drug, M‐30, for the treatment of Alzheimer's disease1Journal of Neurochemistry, 2006
- Down-regulation of Endogenous Amyloid Precursor Protein Processing due to Cellular AgingJournal of Biological Chemistry, 2006
- Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 ratsJournal of Neural Transmission, 2002
- Selectivity of Cholinesterase InhibitionCNS Drugs, 1999
- Induction of behavioral supersensitivity to apomorphine by DFP treatmentLife Sciences, 1981